#USA #Richmond #Indivior #SUBLOCADE #opioid use disorder

Indivior PLC Joins the S&P SmallCap 600 Index

Indivior PLC, a leader in the treatment of opioid use disorder, has officially announced its addition to the S&P SmallCap 600 Index, effective immediately. This marks a pivotal moment for the company, as it continues to focus on transforming lives with its innovative treatments. The CEO, Joe Ciaffoni, expressed that this milestone enhances the company's visibility in the capital markets and aligns perfectly with their strategic business profile in the U.S.

Significance of Inclusion in the Index

The S&P SmallCap 600 Index, established by Standard & Poor's, is designed to measure the performance of small-cap stocks. Inclusion in this index requires meeting rigorous standards, ensuring that only financially stable and liquid companies are represented. For Indivior, this recognition not only improves market perception but also underscores its commitment to expanding access to life-changing medications, particularly its top product, SUBLOCADE.

Focus on Opioid Use Disorder

Indivior is on a mission to combat the opioid crisis that has impacted countless lives. As part of their strategy, the company is dedicated to growing the use of SUBLOCADE, a first-in-class long-acting injectable treatment specifically designed for moderate to severe opioid use disorder. Ciaffoni highlighted the company’s commitment to leveraging a simplified operating model to enhance growth and patient access.

The Road Ahead

Looking forward, Indivior is committed to not only improving its existing product portfolio but also developing new treatment options for opioid use disorder. The company’s pipeline includes several promising candidates aimed at expanding its impact in this critical area of healthcare. Their focus on evidence-based solutions positions Indivior as a frontrunner in transforming opioid use disorder into a manageable chronic condition rather than a crisis.

Conclusion

Indivior’s inclusion in the S&P SmallCap 600 Index signals a bright future for the company as it continues to innovate in the pharmaceutical landscape. The commitment to providing effective treatment solutions for opioid use disorder is a testament to Indivior's dedication to patient care and market leadership. As they embark on this new chapter within the healthcare sector, the industry and patients alike look forward to what’s next for Indivior PLC.

For more information about Indivior and its dedication to treating opioid use disorder, visit Indivior's official website. Connect with Indivior on LinkedIn for updates on their progress towards enhancing patient care.